

# CD58 loss in tumor cells confers functional impairment of CAR T cells

Xin Yan,<sup>1,2,\*</sup> Deyun Chen,<sup>1,\*</sup> Xinran Ma,<sup>1,2,\*</sup> Yao Wang,<sup>1,\*</sup> Yelei Guo,<sup>1</sup> Jianshu Wei,<sup>1</sup> Chuan Tong,<sup>1</sup> Qi Zhu,<sup>1</sup> Yuting Lu,<sup>1</sup> Yang Yu,<sup>4</sup> Zhiqiang Wu,<sup>1</sup> and Weidong Han<sup>1-3</sup>

<sup>1</sup>Department of Bio-therapeutic, the First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China; <sup>2</sup>School of Medicine, Nankai University, Tianjin, China; <sup>3</sup>National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University; and <sup>4</sup>Department of Transfusion Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing, China

## Key Points

- We emphasized the potential critical role of CD58 loss in resistance to CAR T-cell therapy.
- Loss of CD58 caused inefficient IS formation with CAR T cells, impairing the activation and cytotoxic function of CAR T cells.

Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in treating a variety of hematologic malignancies, but resistance to this treatment in some patients limited its wider application. Using an unbiased genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) screening, we identified and validated loss of CD58 conferred immune evasion from CAR T cells in vitro and in vivo. CD58 is a ligand of the T-cell costimulatory molecule CD2, and CD58 mutation or downregulated expression is common in hematological tumors. We found that disruption of CD58 in tumor cells induced the formation of suboptimal immunological synapse (IS) with CAR T cells, which conferred functional impairment of CAR T cells, including the attenuation of cell expansion, degranulation, cytokine secretion, and cytotoxicity. In summary, we describe a potential mechanism of tumor-intrinsic resistance to CAR T-cell therapy and suggest that this mechanism may be leveraged for developing therapeutic strategies to overcome resistance to CAR T-cell therapy in B-cell malignancies.

## Introduction

Chimeric antigen receptor (CAR) T-cell therapy has demonstrated unprecedented success in the treatment of B-cell malignancies, especially CD19-targeted CAR T-cell therapy for acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL).<sup>1-5</sup> Notwithstanding some progress achieved, primary or acquired resistance to the treatment still occurs.<sup>1,6</sup> A deeper exploration for resistance mechanisms to CAR T-cell therapy may provide diverse rationales for patient selection or potential strategies.

Target antigen evasion has been confirmed as a mechanism for acquired resistance to CAR T-cell therapy.<sup>7-10</sup> Increasing evidence has suggested that the mechanisms of primary resistance to CAR T-cell therapy involve CAR T-cell defects, including impaired proliferative capacity, an exhaustion phenotype, and attenuated T-cell-mediated cytotoxicity.<sup>2,11,12</sup> Nevertheless, intrinsic mechanisms of primary resistance of tumor cells to the treatment remain largely elusive.

High-throughput clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-based screening is a powerful tool that provides unbiased critical genetic data to exploit for the reasons for resistance to CAR T-cell therapy or to find new biomarkers for stratifying patients. To identify tumor cell-intrinsic factors that determine resistance to CAR T-cell cytotoxicity, we

Submitted 18 April 2022; accepted 15 June 2022; prepublished online on *Blood Advances* First Edition 21 June 2022. <https://doi.org/10.1182/bloodadvances.2022007891>.


\*X.Y., D.C., X.M., and Y.W. contributed equally to this study.

The RNA sequencing data reported in this article have been deposited in the Gene Expression Omnibus database (accession number GSE201970).

All data that support the findings of this study are available to the researchers on reasonable request.

The full-text version of this article contains a data supplement.

© 2022 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.



**Figure 1. Use of CRISPR/Cas9 screening to study intrinsic tumor resistance mechanisms to CAR T cells.** (A) Schematic showing the CRISPR/Cas9 screening process. (B) The 10 genes with the most significant sgRNA enrichment. (C) Log<sub>2</sub> fold change of normalized counts of each sgRNA targeting CD58, CD81, ICAM1, or ITGA4 in the screening. (D) Efficacy of CD58, CD81, ICAM1, or ITGA4 KO in Nalm6 cells. (E-H) GFP-labeled indicated KO cells and mCherry-labeled WT cells were mixed at a ~1:1 ratio and cocultured with control T or CAR T cells. The KO (GFP<sup>+</sup>)/WT (mCherry<sup>+</sup>) ratio was calculated over time. CD58<sup>KO</sup>/WT Nalm6 ratio (E), CD81<sup>KO</sup>/WT Nalm6 ratio (F), ICAM1<sup>KO</sup>/WT Nalm6 ratio (G), and ITGA4<sup>KO</sup>/WT Nalm6 ratio (H) in growth competition assay. KO cell lines referred to sgRNA-1 targeting the indicated genes in panels E-H. A mixture of cells was cocultured with control T or CD19 CAR T cells at a 1:20 E:T ratio (n = 3). Statistical comparisons were performed using a 2-way ANOVA test with multiple comparisons. The values are shown as the means plus or minus SD. \**P* < .05; \*\**P* < .01; \*\*\* *P* < .001. ns, not significant (*P* > .05); RRA, Robust Rank Aggregation.

performed unbiased genome-wide CRISPR/Cas9 screening with a coculture model consisting of Nalm6 cells and CD19 CAR T cells. We revealed that CD58, a ligand for the CD2 receptor expressed on T cells,<sup>13</sup> plays a key role in resistance to CAR T-cell therapy in preclinical tests. Disruption of CD58 in tumor cells impaired immunological synapse (IS) formation with CAR T cells, which led to the dysfunction of CAR T cells, including attenuated CAR signal transduction, CAR T-cell expansion, and cytotoxicity. Taken together, these findings suggest a potential mechanism for resistance to CAR T-cell therapy.

## Materials and methods

Additional materials and methods are provided in supplemental Materials.

## CRISPR/Cas9 screening

The process of CRISPR/Cas9 screening has been described in our previous report.<sup>14</sup> Briefly, Nalm6 cells were transfected with lentivirus carrying the Brunello library,<sup>15</sup> and cells exhibiting stable lentivirus integrations were selected with puromycin. Transduced Nalm6 cells were cultured with CD19 CAR T cells or control T cells at a 1:50 effector:target (E:T) ratio. Control T or CD19 CAR T cells were added to the culture at a 1:50 E:T ratio every 3 days. The cells were collected using a death cell removal magnetic bead kit (Miltenyi) for genomic DNA analysis on day 15. After removing low-quality reads from the original sequencing data, the reads were mapped to single-guide RNA (sgRNA) sequence, and each sgRNA read was counted to generate a sgRNA count table. sgRNA data in the sgRNA table was normalized and used for significance analysis. sgRNA read




Figure 2.

counts were analyzed with the MAGeCK v0.5.7 algorithm. Genes with significantly enriched sgRNAs were identified based on a  $\log_2$  fold change and  $P$  value criteria. Hypergeometric distribution statistics were used to identify gene sets that overlapped with candidate genes ( $\log_2$  fold change  $> 2$  and  $P < .05$ ).

### Blocking experiment

Cells were pretreated with blocking monoclonal antibody (mAb) against CD58 (clone TS2/9, 8  $\mu\text{g}/\text{mL}$ , BioLegend) or CD2 (clone RPA-2.10, 10  $\mu\text{g}/\text{mL}$ , eBioscience) or with isotype-matched control mAbs for 30 minutes. The blocking effect was detected by staining for anti-CD58-PE (BioLegend) or anti-CD2-APC-Cy7 (BioLegend). Tumor cells blocked by anti-CD58 mAbs or CAR T cells blocked by anti-CD2 mAbs were subjected to subsequent experiments, including cytotoxicity assays and degranulation assays, according to the methods described above.

### Imaging flow cytometry

The sorted CD19 CAR T cells were stained with 0.2  $\mu\text{M}$  CellTrace Violet dye (Thermo Fisher Scientific) in accordance with the manufacturer's instructions. A total of  $1 \times 10^6$  wild-type (WT) (mCherry<sup>+</sup>) Nalm6,  $1 \times 10^6$  CD58 knockout (KO) (GFP<sup>+</sup>) Nalm6 and  $1 \times 10^6$  CD19 CAR T cells (Violet<sup>+</sup>) were cocultured at 37°C for the indicated times, fixed, permeabilized, and then stained with phalloidin-AF647 (Thermo Fisher Scientific) for detecting F-actin. A total of  $1 \times 10^6$  events were recorded, and samples were analyzed with an ImageStreamX MKII flow cytometer (Luminex). Image acquisition and data analysis<sup>16,17</sup> was performed using IDEAS software version 6.2. The calculation formula for measuring IS is as follows: F-actin enrichment at IS (%) =  $100 \times (\text{intensity of phalloidin at IS}) / (\text{intensity of phalloidin-stained CAR T cells})$

### Xenograft mouse models

A total of  $1 \times 10^5$  luciferase<sup>+</sup> Nalm6 cells (WT or CD58<sup>KO</sup>) were IV transplanted into 4- to 6-week-old female NOD-Prkdc-scid-Il2rg-null mice (NPG/Vst, VITALSTAR). Purified CD19 CAR T cells were selected using magnetic beads (Miltenyi Biotec) 3 days post-lentiviral infection. Seven days after Nalm6 cell injection, the mice were IV injected with  $1 \times 10^6$  CD19 CAR T or control T cells in 100  $\mu\text{l}$  of phosphate-buffered saline (PBS) ( $n = 6$  mice per group). Leukemia

burden was monitored once per week by bioluminescence in vivo imaging (BLI) with an in vivo imaging system (IVIS) (PerkinElmer). The average flux (photons per second/area [ $\text{mm}^2$ ]) was used to evaluate the BLI signal. Mouse peripheral blood samples were collected through the orbital sinus and lysed using ammonium chloride-potassium (ACK) lysing buffer (Thermo Fisher Scientific). The remaining cells were stained with the indicated fluorochrome-conjugated antibodies. All studies were approved by the Institutional Animal Care and Treatment Committee of the Chinese People's Liberation Army General Hospital.

### Statistical analysis

Statistical analyses were conducted using GraphPad Prism 6. Statistical tests were performed using a 2-tailed  $t$  test, 1-way analysis of variance (ANOVA) test, and 2-way ANOVA test with Bonferroni correction to compare the significant differences. Survival analysis was analyzed using the log-rank test. Unless otherwise indicated,  $P \leq .05$  was considered statistically significant for all analyses. All group values are represented as means plus or minus standard deviation (SD) if not stated otherwise.

## Results

### CRISPR screening reveals critical regulators that determine resistance to CAR T-cell therapy

To systematically identify critical regulators that determine resistance to CAR T-cell therapy in tumor cells, we conducted genome-wide CRISPR/Cas9 screening with a coculture model containing Nalm6 cells, CD19<sup>+</sup> human pre-B ALL cells, and CD19 CAR T cells (Figure 1A). The Nalm6 cells were transduced with a lentiviral CRISPR Brunello library targeting ~19 000 genes and then selected under puromycin pressure for 2 days. To better reflect the long-term high tumor burden in vivo, Nalm6 cells were supplemented with CD19 CAR T cells every 3 days for 15 days at a 1:50 E:T ratio.<sup>18</sup> To avoid contamination by the enrichment of sgRNAs that are associated with tumor cell survival but not with CAR T-cell therapy, we cocultured Nalm6 cells that had been transduced with the aforementioned CRISPR library with control T cells as the control condition. The composition of the sgRNAs in surviving tumor cells under CAR T-cell or control T-cell treatment conditions

**Figure 2. Role of CD58 in resistance to CAR T-cell-mediated killing.** (A-C) CD58<sup>KO</sup>/WT Nalm6 cell ratio in growth competition assays. CD58<sup>KO</sup> Nalm6 cells referred to sgCD58-2 Nalm6 cells. (A) A mixture of Nalm6 cells were cocultured with control T cells or CD20 CAR T cells at a 1:1 E:T ratio ( $n = 3$ ). (B) A mixture of Nalm6 cells were cocultured with control T cells or tandem CD19/20 CAR T cells at a 1:20 E:T ratio ( $n = 3$ ). (C) A mixture of Nalm6 cells were cocultured with control T cells or CD19.28z CAR T cells at a 1:20 E:T ratio ( $n = 4$ ). (D-G) CD58<sup>KO</sup>/WT Raji cell ratio in a growth competition assay. CD58<sup>KO</sup> Raji cells referred to sgCD58-2 Raji cells. (D) A mixture of Raji cells were cocultured with control T cells or CD19 CAR T cells at a 1:20 E:T ratio ( $n = 3$ ). (E) A mixture of Raji cells were cocultured with control T cells or CD20 CAR T cells at a 1:20 E:T ratio ( $n = 3$ ). (F) A mixture of Raji cells were cocultured with control T cells or CD19/20 CAR T cells at a 1:20 E:T ratio ( $n = 4$ ). (G) A mixture of Raji cells were cocultured with control T cells or CD19.28z CAR T cells at a 1:20 E:T ratio ( $n = 4$ ). (H) Cytotoxic analysis of WT and CD58<sup>KO</sup> Nalm6 cells cocultured with CD19 CAR T cells at indicated E:T ratios for 24 hours ( $n = 3$ ). (I) Cytotoxic analysis of WT and CD58<sup>KO</sup> Nalm6 cells cocultured with CD19/20 CAR T cells at indicated E:T ratios for 24 hours ( $n = 4$ ). (J) Cytotoxic analysis of WT and CD58<sup>KO</sup> Nalm6 cells cocultured with CD19.28z CAR T cells at indicated E:T ratios for 24 hours ( $n = 4$ ). (K) Cytotoxic analysis of WT and CD58<sup>KO</sup> Raji cells cocultured with CD19 CAR T cells at indicated E:T ratios for 24 hours ( $n = 4$ ). (L) Cytotoxic analysis of WT and CD58<sup>KO</sup> Raji cells cocultured with CD19/20 CAR T cells at indicated E:T ratios for 24 hours ( $n = 4$ ). (M) FACS histogram showing the CD58 level in Nalm6 or Raji cell lines pretreated with control or blocking anti-CD58 mAbs for 30 minutes. (N) Cytotoxic analysis of Nalm6 or Raji cells pretreated with control or anti-CD58-blocking mAbs and cocultured with CD19 CAR T cells for 24 hours at a 1:20 E:T ratio ( $n = 3$ ). (O) Representative FACS histogram showing the CD2 level in CD19 CAR T cells pretreated with control or anti-CD2-blocking mAbs for 30 minutes. (P) Cytotoxicity analysis of Nalm6 or Raji cells cocultured with control or anti-CD2 mAb-blocked CD19 CAR T cells at a 1:20 E:T ratio for 24 hours ( $n = 3$ ). (Q) Representative FACS plot showing the level of CD19 expression in WT and CD58<sup>KO</sup> cell lines. (R) Representative FACS plot showing the level of CD20 expression in WT and CD58<sup>KO</sup> cell lines. Significance was assessed using a 2-way ANOVA test with multiple comparisons in panels A-L. Statistical comparisons were performed using a 2-tailed unpaired  $t$  test in panels N and P. The values are shown as the means plus or minus SD. \* $P < .05$ ; \*\* $P < .01$ ; \*\*\* $P < .001$ . FACS, fluorescence-activated cell sorter; ns, not significant ( $P > .05$ ).




Figure 3.

was evaluated by Illumina sequencing and analyzed by MAGeCK algorithm (supplemental Table 1).<sup>19</sup> Our CRISPR screening identified expected candidates among the top 10 hits, namely CD19,<sup>7,8,20</sup> JAK2,<sup>21</sup> and CASP8,<sup>22</sup> consistent with known mechanisms of resistance to CD19-targeted immunotherapies (Figure 1B). Interestingly, a cluster of membrane protein genes, including CD58, ICAM1, CD81, and ITGA4 were also positively selected (Figure 1C). In order to verify our screening findings, we generated stable KO cell lines of membrane proteins (CD58, CD81, ICAM1, and ITGA4) in Nalm6 cells by the CRISPR/Cas9 technology (Figure 1D). Growth competition assays were conducted for WT or KO target cell lines with different fluorescence labels in the presence of CAR T cells. The growth competition assays revealed that CD58<sup>KO</sup> and CD81<sup>KO</sup> cells conferred progressive enrichment in the presence of CD19 CAR T cells compared with WT cells (Figure 1E-F; supplemental Figure 1A-B). However, ICAM1<sup>KO</sup> and ITGA4<sup>KO</sup> cells did not show a significant increase (Figure 1G-H; supplemental Figure 1C-D). We identified that CD81 loss induced disruption of CD19 membrane trafficking (supplemental Figure 2). This finding is similar to previous reports in which downregulation of CD81 has been identified as a mechanism for resistance to CD19-targeted therapy.<sup>20,23</sup> In the current study, we focused on the role of CD58 in CAR T-cell therapy.

### Loss of CD58 in tumor cells induces resistance to CAR T-cell therapy

To explore whether CD58-deficient tumor cells were resistant to CAR T-cell therapy with different CAR design, we also generated distinct CAR T cells including CD20 CAR T, tandem CD19/CD20 CAR T cells,<sup>24</sup> and CD19.28z CAR T cells from multiple healthy donors and observed that both CD58 loss in Nalm6 cells and Raji cells were relatively resistant to CAR T cells (Figure 2A-G; supplemental Figures 3 and 4A-J). We also found that tumor cells with disruption of CD58 exhibited low sensitivity to CAR T-cell-mediated killing in a cytotoxicity assay (Figure 2H-L; supplemental Figure 2K-M). This effect was recapitulated with an anti-CD58-blocking mAb (Figure 2M-N). Notably, blockage of CD2 on CAR T cells resulted in impaired CAR T-cell-mediated cytotoxicity (Figure 2O-P). As expected, resistance was not attributed to the downregulation of CD19 expression or CD20 expression, as determined by flow cytometry (Figure 2Q-R). Additionally, we observed that knocking out CD58 had no effect on the proliferation

or apoptosis of tumor cells (supplemental Figure 5A-C). However, CD58 loss did not protect tumor cells from chemotherapy-mediated killing (supplemental Figure 5D), implying that CD58 loss in tumor cells may specifically confer resistance to CAR T-cell-mediated killing. Collectively, these findings imply that the CD58-CD2 axis is necessary in cytotoxic killing by CAR T cells and that lack of CD58 in lymphoid cancer cells could induce resistance to CAR T-cell therapy.

### CD58 disruption in tumor cells impairs CAR T cells

The CD58-CD2 interaction has been reported to be a crucial costimulatory signal for T-cell activation in response to target cells.<sup>25</sup> Using TCGA RNA sequencing data and Tumor Immune Estimation Resource 2.0, (TIMER),<sup>26</sup> we found that messenger RNA levels of CD58 were positively correlated with CD8 T-cell infiltration in many human cancer types (supplemental Figure 6A). Besides, we found that the low expression of CD58 was associated with the low expression of interferon  $\gamma$  (IFN- $\gamma$ ) and tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) (supplemental Figure 6B-C), which suggested that the downregulated expression of CD58 in tumor cells may be related to the dysfunction of T cells. Hence, we wondered whether resistance to CAR T-cell therapy caused by CD58 disruption in cancer cells is due to attenuated CAR T-cell function. We found decreased expansion of CD19 CAR T cells cocultured with CD58<sup>KO</sup> Nalm6 cells or CD58<sup>KO</sup> Raji cells (Figure 3A-B). We also observed that lack of CD58 in tumor cells initiated dysfunctional degranulation, as measured by CD107a level (Figure 3B; supplemental Figure 7A). In parallel, adding an anti-CD58-blocking mAb to Nalm6 cell cultures and an anti-CD2-blocking mAb to CD19 CAR T-cell cultures significantly inhibited degranulation (Figure 3C-D). Moreover, we found that loss of CD58 in tumor cells led to the reduced secretion of cytokines, such as interleukin-2 (IL-2), TNF- $\alpha$ , and IFN- $\gamma$  (Figure 3E; supplemental Figure 7B). To further explore the effect of tumor cells with disrupted CD58 on CAR T cells, we sorted CAR T cells cultured with WT or CD58<sup>KO</sup> tumor cells and then tested their kinetic responses when cocultured with WT tumor cells (Figure 3F). Remarkably, we found that CD19 CAR T cells initially cultured with CD58<sup>KO</sup> tumor cells exhibited low expansion capacity, a reduced degranulation, and impaired ability to kill WT tumor cells again (Figure 3G-J; supplemental Figure 8A-D). We also noted increased apoptosis in CD19 CAR T cells initially cultured with CD58<sup>KO</sup> tumor cells, and this increased apoptosis

**Figure 3. Loss of CD58 in tumor cells gives rise to CAR T-cell dysfunction.** (A) Expansion of CD19 CAR T cells after coculturing with WT or CD58<sup>KO</sup> Nalm6 or Raji cells at a 1:1 E:T ratio (n = 3). (B) FACS-based measurement of CD107a expression in CD19 CAR T cells stimulated by WT or CD58<sup>KO</sup> Nalm6 or Raji cells (n = 4). (C) FACS-based measurement of CD107a expression in CD19 CAR T cells stimulated with Nalm6 or Raji cells pretreated with control or anti-CD58-blocking mAbs (n = 4). (D) FACS-based measurement of CD107a expression in CD19 CAR T cells pretreated with control or anti-CD2-blocking mAbs after stimulation with Nalm6 cells or Raji cells (n = 4). (E) FACS-based quantification of intracellular interleukin-2, IFN- $\gamma$ , and TNF- $\alpha$  expression in CD19 CAR T cells stimulated with WT or CD58<sup>KO</sup> Nalm6 cells (n = 4) or Raji cells (n = 5) at a 1:1 E:T ratio for 8 hours. (F) Schematic showing the functional assessment study. CD19 CAR T cells and WT or CD58<sup>KO</sup> Nalm6 cells were initially cocultured at an E:T ratio of 1:1 for 3 days (first coculture). CD19 CAR T cells were sorted by the phycoerythrin magnetic beads method based on CAR staining in first coculture and then cocultured again with WT Nalm6 cells at an E:T ratio of 1:1 for 24 hours and 48 hours (secondary coculture). Expansion (G) and Ki67 expression (H) of CD19 CAR T cells after 24 hours and 48 hours in secondary coculture (n = 3). (I) CD19 CAR T cells were sorted in first coculture and then cocultured again with WT Nalm6 cells at an E:T ratio of 1:1 to test the degranulation (CD107a expression) of CAR T cells for 0.5 hours or 1 hour (n = 4). (J) Survival of WT Nalm6 cells after 24 hours and 48 hours in secondary coculture (n = 3). (K) Representative FACS plots and quantification of annexin V expression of CD19 CAR T cells after 24 hours and 48 hours in secondary coculture (n = 3). (L) Pattern of repeated antigen stimulation in vitro. (M) CD19 CAR T-cell expansion after repeated stimulation with WT or CD58<sup>KO</sup> Nalm6 cells. CD25 (N) and CD69 expression (O) in CD19 CAR T cells after repeated stimulation with WT or CD58<sup>KO</sup> Nalm6 cells (n = 3). Statistical comparisons were performed using a 2-tailed unpaired *t* test in panels C-D. Statistical comparisons were performed using a 1-way ANOVA test in panels B and E. Significance was assessed using a 2-way ANOVA test with multiple comparisons in panels A, G-K, and M-O. The values are shown as the means plus or minus SD. \**P* < .05; \*\**P* < .01; \*\*\**P* < .001. †, the time point when WT or CD58<sup>KO</sup> Nalm6 or Raji cells were added; 7-AAD-Percp, 7-Aminoactinomycin D (Peridinin-Chlorophyll-Protein Complex); FACS, fluorescence-activated cell sorter; ns, not significant (*P* > .05).




Figure 4.

was not driven by FAS or TNFR2 upregulation (Figure 3K; supplemental Figure 8E-F). To investigate the effect of chronic CD58<sup>KO</sup> tumor cell stimulation on the function of CAR T cells, we established a coculture system in which WT or CD58<sup>KO</sup> tumor cells were added to a CAR T-cell culture every 72 hours (Figure 3L). Repetitive CD58<sup>KO</sup> tumor cell stimulation attenuated CAR T-cell expansion and reduced CAR T-cell activation as measured by Ki67, CD25, and CD69 level (Figure 3M-O; supplemental Figure 8G-K). Overall, these results suggest that CD58 disruption in cancer cells conferred functional impairment of CAR T cells, including reduced CAR T-cell expansion, survival, activation, degranulation, cytotoxicity, and cytokine secretion and increased CAR T-cell death, which might be responsible for resistance to CAR T-cell therapy.

### CD58-deficient tumor cells prevent effective IS formation with CAR T cells and attenuate CAR signaling transduction

The CD2-CD58 interaction is essential for the formation of effective IS, to sustaining the activation and proliferation of T cells and trigger a series of intracellular signaling pathways in T cells.<sup>25</sup> Recent studies have revealed that nonclassical IS formed by CAR T cells and tumor cells has been regarded as an important indicator for predicting the effectiveness of CAR T-cell therapy.<sup>27-29</sup> Therefore, we hypothesized that the inhibition of CAR T-cell function induced by CD58-deficient tumor cells is caused by the ineffective formation of IS and weakened CAR signaling strength. To test this hypothesis, we performed an in vitro conjugation assay.<sup>30</sup> Compared with WT cells, CD58<sup>KO</sup> Nalm6 cells formed significantly fewer conjugates with CAR-expressing Jurkat cells or CAR T cells (Figure 4A; supplemental Figure 9).

Next, we used high-throughput imaging flow cytometry (ImageStream) to evaluate the stability of IS (Figure 4B). CD58<sup>KO</sup> Nalm6 cells formed IS structures with potentially disadvantageous cytoskeletal properties, as measured by F-actin intensity and enrichment at the IS (Figure 4C-D), implying that CD58<sup>KO</sup> Nalm6 cells prevented effective IS formation with CAR T cells.

Considering that the production of CAR T cells requires the activation of anti-CD3 antibody, the addition of anti-CD3 antibody caused high background phosphorylation level and we could not detect differences between groups. Therefore, we observed that the phosphorylation of CD3 $\zeta$ -CAR, LCK, or ZAP70 in CAR-expressing Jurkat cells stimulated with CD58<sup>KO</sup> Nalm6 cells was inhibited compared with that stimulated with WT Nalm6 cells (Figure 4E). Of

note, an anti-CD2 antibody can activate CAR T cells by detecting the expression of CD25 in CAR T cells (supplemental Figure 10A). However, CD58 loss in tumor cells did not show increased sensitivity to CAR T cells after the addition of an anti-CD2 antibody (supplemental Figure 10B), indicating the stable IS formed by CD58 on tumor cells is necessary for CAR T cells to successfully kill tumor cells.

To decipher the underlying molecular programs accounting for CD58-deficient tumor-mediated CAR T-cell dysfunction, we leveraged the transcriptional profiles of CD19 CAR T cells cocultured with WT Nalm6 cells or CD58<sup>KO</sup> Nalm6 cells. We observed differentially expressed genes in CD19 CAR T cells stimulated with WT Nalm6 cells or CD58<sup>KO</sup> Nalm6 cells (supplemental Figure 11A). A gene enrichment analysis of these differentially expressed genes revealed that these genes were significantly enriched in regulation of cell adhesion, T-cell activation, cytokine-related signaling, and cell proliferation (Figure 4F; supplemental Figure 11B-C; supplemental Table 2). More specifically, CD19 CAR T cells cocultured with CD58<sup>KO</sup> Nalm6 cells showed marked downregulation of genes associated with activation (RIPOR2, IL1A, RUNX1, NFKB2, SDC4, and TNFRSF4)<sup>31-35</sup> and significantly differentially expressed genes associated with T-cell differentiation (CXCR4, CCR7, TOX, LGALS3, and XBP1).<sup>36-38</sup> In addition, we found that the expression of a cluster of cytokine genes (IFNG, TNF, IL17F, IL13, CCL3L3, and CCL5) was decreased in CAR T cells cocultured with CD58<sup>KO</sup> Nalm6 cells (Figure 4G). Taken together, these findings indicate that CD58<sup>KO</sup> tumor cells and CAR T cells form inefficient IS, which drives a reduction in CAR T-cell activation, resulting in CAR T-cell dysfunction.

### Loss of CD58 in tumor cells exhibits resistance to CAR T-cell therapy in vivo

To evaluate the effect of CD58<sup>KO</sup> tumor cells on the anti-tumor ability of CAR T-cell therapy in mouse xenograft models, we examined the tumor-suppressive ability of equal amounts of CAR T cells in mice transplanted with WT tumor cells or CD58<sup>KO</sup> tumor cells (Figure 5A). Consistent with our in vitro observations, the CD19 CAR T cells in CD58<sup>KO</sup> Nalm6 cell-bearing mice showed low tumor clearance capacity (Figure 5B-C). Moreover, xenograft mice with CD58<sup>KO</sup> Nalm6 cell transplants exhibited a survival disadvantage compared with xenograft mice with WT Nalm6 cell transplants (Figure 5D). Consistently, the expansion of CAR T cells in peripheral blood in CD58<sup>KO</sup> tumor-bearing mice was significantly lower than that in WT tumor-bearing mice (Figure 5E). Besides, we found that loss of CD58 in tumor cells suppressed activation of

**Figure 4. KO of CD58 in tumor cells forms ineffective IS with CAR T cells and attenuates CAR signaling.** (A) CD19 CAR T cells were stained with CellTrace Violet dye and incubated with WT Nalm6 (mCherry+) and CD58<sup>KO</sup> (GFP+) Nalm6 cells for 10 minutes or 30 minutes. Representative FACS and bar plots (gating from Violet<sup>+</sup> cells) representing the quantification of conjugates formed by WT or CD58<sup>KO</sup> with CAR T cells (n = 3). (B) CD19 CAR T cells prestained with CellTrace Violet dye were cocultured with WT (mCherry+) or CD58<sup>KO</sup> (GFP+) Nalm6 cells for 10 minutes or 30 minutes. After incubation, the cells were analyzed for the expression of CellTrace Violet, GFP, mCherry, and phalloidin (AF647) using ImageStream. Phalloidin was used to stain F-actin. The gating strategy used for the identification of IS and a representative image of an IS are shown. The white arrow points to an IS. (C) Median fluorescence intensity (MFI) of phalloidin at IS (n = 3). (D) F-actin enrichment at IS with WT or CD58<sup>KO</sup> is reported as percent protein (n = 3). (E) Proximal signaling events of CAR-expressing Jurkat cells upon stimulation with WT or CD58<sup>KO</sup> Nalm6 cells. Similar results were obtained from 3 independent biological experiments. (F) Selected pathways of gene ontology enrichment analysis in the biological process category of differentially expressed genes in CD19 CAR T cells sorted by flow cytometry 3 days after stimulation with WT or CD58<sup>KO</sup> Nalm6 cells (n = 2 different peripheral blood mononuclear cell donors). (G) Heatmap showing select differentially expressed genes related to T-cell activation, T-cell differentiation, and cytokines in CD19 CAR T cells after 3 days of stimulation with WT or CD58<sup>KO</sup> Nalm6 cells (n = 2 different PBMC donors). Statistical comparisons were performed using a 2-way ANOVA test with multiple comparisons. The values are shown as the means plus or minus SD. \**P* < .05; \*\**P* < .01; \*\*\**P* < .001. FACS, fluorescence-activated cell sorter; KO-FITC, CD58<sup>KO</sup> cells (Fluorescein Isothiocyanate); ns, not significant (*P* > .05); WT-PE, WT cells (phycoerythrin).






Figure 5.

CAR T cells, as measured by CD25 level (Figure 5F). CAR T cells in the CD58<sup>KO</sup> tumor group secreted fewer cytokines than those in the WT tumor group (Figure 5G). These results indicate that loss of CD58 in tumor cells results in reduced sensitivity to CD19 CAR T-cell therapy *in vivo*.

## Discussion

Resistance to CAR T-cell therapy is a primary obstacle to its broader therapeutic use.<sup>39</sup> Performing unbiased CRISPR/Cas9 screening with the Nalm6 cells, CD19<sup>+</sup> human ALL cell line, we revealed several genetic perturbations potentially capable of mediating resistance to CAR T-cell therapy. In addition to antigen loss and T-cell dysfunction, tumor-intrinsic resistance mechanisms, such as impaired death receptor signaling and NOXA, have been recently reported.<sup>18,22,40</sup> In the present study, we identified a potential mechanism of tumor-intrinsic resistance to CAR T-cell therapy mediated by the loss of CD58 in tumor cells.

CD58 is a member of the immunoglobulin superfamily and is a ligand for the costimulatory molecule CD2 expressed in T cells.<sup>41</sup> Disruption of the CD58-CD2 axis by blocking antibodies results in decreased T-cell activation, reduced IFN- $\gamma$  secretion, and reduced cytotoxicity.<sup>42,43</sup> Several reports have shown that loss of CD58 in tumor cells is an unfavorable prognostic factor and a frequent genetic abnormality in patients with hematologic malignancies.<sup>44,45</sup> On the basis of CRISPR/Cas9 screening, a recent study has revealed that CD58 loss can confer immune evasion in tumor-infiltrating lymphocyte-mediated killing and that CD58 expression is downregulated in tumors of melanoma patients with resistance to immune checkpoint inhibitors.<sup>46</sup> Likewise, CRISPR/Cas9 screening was implemented showed that CD58 deletion caused Nalm6 cell escape from natural killer cell-mediated killing in another study.<sup>47</sup> These data suggest that abnormal CD58 expression in tumor cells may confer general resistance to various immunotherapies and that further investigation is needed in future studies.

CD58 is essential for the formation of stable IS, maintenance of T-cell activation, T-cell survival, and T-cell-mediated killing.<sup>25,48</sup> However, the effect of CD58 expression in tumor cells on CAR T-cell therapy remains unknown. In this study, we observed that CD58<sup>KO</sup> in 2 B-lymphoid cell lines showed significantly less sensitive to a series of CAR T cells, including CD19 CAR T, CD20 CAR T, and tandem CD19/20 CAR T cells. In addition, we found that the loss of CD58 in tumor cells triggered impaired CAR T cells, which resulted in decreased CAR T-cell proliferation, degranulation, cytokine secretion, and cytotoxic effects and increased cell death. Even if the structure of IS formed by CAR T cells and target cells is saliently distinct from that the structure of classical IS, but

an increasing number of studies demonstrated that the IS formed by CAR T cells plays an important role in driving the cytotoxic function of CAR T cells.<sup>27-29,49,50</sup> In this study, we observed that CD58 loss in tumor cells prevented effective IS formation with CAR T cells, as measured by the intensity and enrichment of F-actin, a key component in IS.<sup>16,51</sup> Furthermore, we found that CAR T cells saliently attenuated CAR signaling and CAR T-cell activation stimulation by CD58-deficient tumor cells. These results may shed light on the reasons that loss of CD58 in tumor cells induces resistance to CAR T-cell therapy.

Unfortunately, we were unable to provide clinical relevance of CD58 protein levels to CAR T-cell therapy in hematologic malignancies. Factually, we detected CD58 protein levels in tumor specimens from 34 patients with B-cell lymphoma before infusions of tandem CD19/20 CAR T cells by immunohistochemistry.<sup>24,52</sup> Unexpectedly, we found only 2 patients with low CD58 expression (data not shown), which is totally distinct from the 60% DLBCL patients of CD58 protein downregulation reported by others<sup>53,54</sup> in the Western population. In addition, we noted a large difference of CD58 mutation frequency in patients with DLBCL between the Chinese population (~5% to 10% mutation rate)<sup>44,55</sup> and Western population (>20% mutation rate).<sup>53,54</sup> Although the 2 patients with CD58 low expression had poor response in our tandem CD19/20 CAR T-cell clinical trial, few sample number limited further comparative analysis. We preliminarily speculate that the expression of CD58 may be affected by racial disparities; CD58 loss or downregulation was not a main contributing factor for resistance to CAR T-cell therapy, just a low-probability event in Chinese patients with DLBCL.

Strategies to overcome tumor resistance to CAR T-cell therapy caused by CD58 loss remains to be further explored. A recent study illuminated that bypassing CD58 loss in tumor cells using a novel CAR T-cell construct integrating CD2 costimulatory domains with CAR molecules may be a potential therapeutic strategy.<sup>56</sup> CD58 is regulated by both genetic and nongenetic factors.<sup>57</sup> A previous study suggested that EZH2 inhibitors can restore epigenetically silenced CD58 expression on the surface of lymphoma cells, which in turn enhance IFN- $\gamma$  secretion by T/natural killer cells.<sup>43</sup> Reversing the functional downregulation of CD58 in tumor cells using drugs such as epigenetic modulators may contribute to novel combinatorial treatment strategies that can improve clinical responses to CAR T-cell therapy.

Overall, our findings emphasize a potential molecular mechanism determining the resistance of B-cell malignancies to CAR T-cell therapy. Our observations suggest that CD58 may be a clinically predictive biomarker for evaluating response to CAR T-cell therapy

**Figure 5. CD58-deficient tumors show decreased sensitivity to CAR T-cell therapy in mouse xenograft model.** (A) Schematic showing the generation of xenograft mouse models. NPG mice ( $n = 6$  per group) were injected IV with  $1 \times 10^5$  WT or CD58<sup>KO</sup> Nalm6-luk cells 7 days after a single IV injection of  $1 \times 10^6$  control T cells or CD19 CAR T cells. Tumor burden was monitored every 7 days with BLI with an IVIS imaging system. (B) IVIS-obtained images showing tumor burden; BLI was performed at the indicated time points. (C) Average radiance measurement at the indicated time points ( $n = 6$ ). (D) Mouse survival was monitored and recorded ( $n = 6$  per group). (E) T-cell persistence in peripheral blood on days 7 and 14 ( $n = 6$ ). (F) FACS-based measurement of CD25 expression in CD19 CAR T cells in peripheral blood on days 7 ( $n = 6$ ). (G) Cytokines in peripheral blood at 7 days after CAR T-cell infusion were measured by enzyme-linked immunosorbent assays ( $n = 6$ ). Significance was assessed using a 2-way ANOVA with multiple comparisons in panels C and E. Log-rank tests were performed to assess the significance of difference in panel D. Statistical comparisons were performed using a 2-tailed unpaired  $t$  test in panel F. Statistical comparisons were performed using a 1-way ANOVA test in panel G. The values are shown as the means plus or minus SD of 6 mice per group. For panels B-G, the results were from 1 of 3 independent experiments. \* $P < .05$ ; \*\* $P < .01$ ; \*\*\* $P < .001$ . FACS, fluorescence-activated cell sorter; MFI, median fluorescence intensity; ns, not significant ( $P > .05$ ).

in hematologic malignancies, and therefore, targeting CD58 may be a novel therapeutic avenue to enhance the sensitivity or overcome resistance to CAR T-cell therapy.

## Acknowledgments

This work was supported in part by the National Natural Science Foundation of China (Nos. 81830002, 82150108, and 31991171) and Translational Research Grant of National Clinical Research Center for Hematologic Diseases (2021WWC04).

## Authorship

Contribution: X.Y., D.C., Y.W., Z.W., and W.H. designed the study; X.Y., D.C., X.M., and Y.W. performed the experiments; Y.W., Y.G.,

J.W., Q.Z., Y.L., Y.Y., and C.T. assisted with the experiments; X.Y., D.C., Z.W., and W.H. analyzed the data and wrote the original manuscript; and all authors reviewed the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: Z.W., 0000-0002-1971-9889; W.H., 0000-0003-3207-3899.

Correspondence: Zhiqiang Wu, Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China; email: [wuzhiqiang1006@163.com](mailto:wuzhiqiang1006@163.com); and Weidong Han, Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China; email: [hanwdrsw@163.com](mailto:hanwdrsw@163.com).

## References

1. Lesch S, Benmehar MR, Cadilha BL, et al. Determinants of response and resistance to CAR T cell therapy. *Semin Cancer Biol.* 2020;65:80-90.
2. Schuster SJ, Bishop MR, Tam CS, et al; JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med.* 2019;380(1):45-56.
3. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncol.* 2019;20(1):31-42.
4. Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. *N Engl J Med.* 2018;378(5):449-459.
5. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med.* 2018;378(5):439-448.
6. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. *Nat Rev Clin Oncol.* 2019;16(6):372-385.
7. Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. *Nat Med.* 2018;24(10):1504-1506.
8. Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. *Cancer Discov.* 2015;5(12):1282-1295.
9. Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. *Nat Med.* 2018;24(1):20-28.
10. Plaks V, Rossi JM, Chou J, et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. *Blood.* 2021;138(12):1081-1085.
11. Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. *J Clin Invest.* 2016;126(6):2123-2138.
12. Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia [published correction appears in *Nat Med.* 2021;27(3):561]. *Nat Med.* 2018;24(5):563-571.
13. Wang JH, Smolyar A, Tan K, et al. Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors. *Cell.* 1999;97(6):791-803.
14. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. *J Clin Invest.* 2011;121(5):1822-1826.
15. Doench JG, Fusi N, Sullender M, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nat Biotechnol.* 2016;34(2):184-191.
16. Wabnitz G, Kirchgessner H, Samstag Y. Qualitative and quantitative analysis of the immune synapse in the human system using imaging flow cytometry. *J Vis Exp.* 2019(143).
17. Balta E, Stopp J, Castelletti L, Kirchgessner H, Samstag Y, Wabnitz GH. Qualitative and quantitative analysis of PMN/T-cell interactions by InFlow and super-resolution microscopy. *Methods.* 2017;112:25-38.
18. Yan X, Chen D, Wang Y, et al. Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. *Signal Transduct Target Ther.* 2022;7(1):98.
19. Li W, Köster J, Xu H, et al. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. *Genome Biol.* 2015;16(1):281.
20. Zhao Y, Aldoss I, Qu C, et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. *Blood.* 2021;137(4):471-484.

21. Arenas EJ, Martínez-Sabadell A, Rius Ruiz I, et al. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. *Nat Commun.* 2021;12(1):1237.
22. Singh N, Lee YG, Shestova O, et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction. *Cancer Discov.* 2020;10(4):552-567.
23. Braig F, Brandt A, Goebeler M, et al. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. *Blood.* 2017;129(1):100-104.
24. Tong C, Zhang Y, Liu Y, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. *Blood.* 2020;136(14):1632-1644.
25. Demetriou P, Abu-Shah E, Valvo S, et al; Oxford IBD Cohort Investigators. A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals [published correction appears in *Nat Immunol.* 2021;22(1):99]. *Nat Immunol.* 2020;21(10):1232-1243.
26. Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. *Genome Biol.* 2016;17(1):174.
27. Liu D, Badeti S, Dotti G, et al. The role of immunological synapse in predicting the efficacy of chimeric antigen receptor (CAR) immunotherapy. *Cell Commun Signal.* 2020;18(1):134.
28. Xiong W, Chen Y, Kang X, et al. Immunological synapse predicts effectiveness of chimeric antigen receptor cells [published correction appears in *Mol Ther.* 2021;29(3):1349-1351]. *Mol Ther.* 2018;26(4):963-975.
29. Davenport AJ, Cross RS, Watson KA, et al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity [published correction appears in *Proc Natl Acad Sci U S A.* 2019;116(22):11075-11076]. *Proc Natl Acad Sci USA.* 2018;115(9):E2068-E2076.
30. Chu C, Wang Y, Zhang X, et al. SAP-regulated T Cell-APC adhesion and ligation-dependent and -independent Ly108-CD3 $\zeta$  interactions. *J Immunol.* 2014;193(8):3860-3871.
31. Fu Y, Lin Q, Zhang Z, Zhang L. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. *Acta Pharm Sin B.* 2020;10(3):414-433.
32. Wong WF, Looi CY, Kon S, et al. T-cell receptor signaling induces proximal Runx1 transactivation via a calcineurin-NFAT pathway. *Eur J Immunol.* 2014;44(3):894-904.
33. Rougerie P, Largeteau Q, Megrelis L, et al. Fam65b is a new transcriptional target of FOXO1 that regulates RhoA signaling for T lymphocyte migration. *J Immunol.* 2013;190(2):748-755.
34. Efenbein A, Simons M. Syndecan-4 signaling at a glance. *J Cell Sci.* 2013;126(Pt 17):3799-3804.
35. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. *Annu Rev Immunol.* 2009;27(1):693-733.
36. Scott AC, Dündar F, Zumbo P, et al. TOX is a critical regulator of tumour-specific T cell differentiation. *Nature.* 2019;571(7764):270-274.
37. Khan AB, Carpenter B, Santos E Sousa P, et al. Redirection to the bone marrow improves T cell persistence and antitumor functions. *J Clin Invest.* 2018;128(5):2010-2024.
38. Pramanik J, Chen X, Kar G, et al. Genome-wide analyses reveal the IRE1a-XBP1 pathway promotes T helper cell differentiation by resolving secretory stress and accelerating proliferation. *Genome Med.* 2018;10(1):76.
39. Singh N, Orlando E, Xu J, et al. Mechanisms of resistance to CAR T cell therapies. *Semin Cancer Biol.* 2020;65:91-98.
40. Dufva O, Koski J, Maliniemi P, et al. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. *Blood.* 2020;135(9):597-609.
41. Binder C, Cvetkovski F, Sellberg F, et al. CD2 immunobiology. *Front Immunol.* 2020;11:1090.
42. Zhang Y, Liu Q, Yang S, Liao Q. CD58 immunobiology at a glance. *Front Immunol.* 2021;12:705260.
43. Otsuka Y, Nishikori M, Arima H, et al. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. *Mol Immunol.* 2020;119:35-45.
44. Cao Y, Zhu T, Zhang P, et al. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors. *Oncotarget.* 2016;7(50):83294-83307.
45. Archimbaud E, Thomas X, Campos L, Magaud JP, Doré JF, Fiere D. Expression of surface adhesion molecules CD54 (ICAM-1) and CD58 (LFA-3) in adult acute leukemia: relationship with initial characteristics and prognosis. *Leukemia.* 1992;6(4):265-271.
46. Frangieh CJ, Melms JC, Thakore PI, et al. Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. *Nat Genet.* 2021;53(3):332-341.
47. Pech MF, Fong LE, Villalta JE, et al. Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. *eLife.* 2019;8:e47362.
48. Daniel PT, Scholz C, Essmann F, Westermann J, Pezzutto A, Dörken B. CD95/Fas-triggered apoptosis of activated T lymphocytes is prevented by dendritic cells through a CD58-dependent mechanism. *Exp Hematol.* 1999;27(9):1402-1408.
49. Strohl WR, Naso M. Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells. *Antibodies (Basel).* 2019;8(3):41.
50. Fousek K, Watanabe J, Joseph SK, et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. *Leukemia.* 2021;35(1):75-89.

51. Mukherjee M, Mace EM, Carisey AF, Ahmed N, Orange JS. Quantitative imaging approaches to study the CAR immunological synapse. *Mol Ther*. 2017; 25(8):1757-1768.
52. Zhang Y, Wang Y, Liu Y, et al. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial. *Leukemia*. 2022;36(1):189-196.
53. Testoni M, Zucca E, Young KH, Bertoni F. Genetic lesions in diffuse large B-cell lymphomas. *Ann Oncol*. 2015;26(6):1069-1080.
54. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. *Nat Genet*. 2011;43(9):830-837.
55. Huo YJ, Xu PP, Fu D, et al. Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication. *Blood Cancer J*. 2022;12(3):48.
56. Majzner RG, Frank MJ, Mount C, et al. CD58 aberrations limit durable responses to CD19 CAR in large B cell lymphoma patients treated with axicabtagene ciloleucel but can be overcome through novel CAR engineering. *Blood*. 2020;136(Supplement 1):53-54.
57. Challa-Malladi M, Lieu YK, Califano O, et al. Combined genetic inactivation of  $\beta$ 2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. *Cancer Cell*. 2011;20(6):728-740.